

University of the Pacific Scholarly Commons

All Dugoni School of Dentistry Faculty Articles

All Faculty Scholarship

2-2-2007

ATP activates a Reactive Oxygen Species-dependent oxidative stress response and secretion of pro-inflammatory cytokines in macrophages

Christiane M. Cruz University of California, Merced

Alessandra Rinna University of California, Merced

Henry Jay Forman University of California, Merced

Ana L. M. Ventura Universidade Federal Fluminense

Pedro M. Persechini Universidade Federal Fluminense, pedromp@biof.ufrj.br

Follow this and additional works at: https://scholarlycommons.pacific.edu/dugoni-facarticles rext page for additional authors Part of the Biochemistry Commons, Immunity Commons, Immunology of Infectious Disease Commons, and the Medical Immunology Commons

Recommended Citation

Cruz, C. M., Rinna, A., Forman, H. J., Ventura, A. L., Persechini, P. M., & Ojcius, D. M. (2007). ATP activates a Reactive Oxygen Species-dependent oxidative stress response and secretion of pro-inflammatory cytokines in macrophages. *Journal of Biological Chemistry, 282*(5), 2871–2879. DOI: 10.1074/jbc.M608083200 https://scholarlycommons.pacific.edu/dugoni-facarticles/122

This Article is brought to you for free and open access by the All Faculty Scholarship at Scholarly Commons. It has been accepted for inclusion in All Dugoni School of Dentistry Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.

Authors

Christiane M. Cruz, Alessandra Rinna, Henry Jay Forman, Ana L. M. Ventura, Pedro M. Persechini, and David M. Ojcius

ATP Activates a Reactive Oxygen Species-dependent Oxidative Stress Response and Secretion of Proinflammatory Cytokines in Macrophages*

Received for publication, August 23, 2006, and in revised form, November 13, 2006 Published, JBC Papers in Press, November 27, 2006, DOI 10.1074/jbc.M608083200

Cristiane M. Cruz^{‡§}, Alessandra Rinna[‡], Henry Jay Forman[‡], Ana L. M. Ventura[¶], Pedro M. Persechini[¶], and David M. Ojcius^{‡1}

From the [‡]School of Natural Sciences, University of California, Merced, California 95344, the [§]Laboratorio de Imunobiofisica, IBCCF, Federal University of Rio de Janeiro, 21949-900 Rio de Janeiro, Brazil, and the [¶]Laboratório de Neuroquímica, Instituto de Biologia, Universidade Federal Fluminense, Niterói 24030-210, Rio de Janeiro, Brazil

Secretion of the proinflammatory cytokines, interleukin (IL)-1 β and IL-18, usually requires two signals. The first, due to microbial products such as lipopolysaccharide, initiates transcription of the cytokine genes and accumulation of the precursor proteins. Cleavage and secretion of the cytokines is mediated by caspase-1, in association with an inflammasome containing Nalp3, which can be activated by binding of extracellular ATP to purinergic receptors. We show that treatment of macrophages with ATP results in production of reactive oxygen species (ROS), which stimulate the phosphatidylinositol 3-kinase (PI3K) pathway and subsequent Akt and ERK1/2 activation. ROS exerts its effect through glutathionylation of PTEN (phosphatase and tensin homologue deleted from chromosome 10), whose inactivation would shift the equilibrium in favor of PI3K. ATP-dependent ROS production and PI3K activation also stimulate transcription of genes required for an oxidative stress response. In parallel, ATP-mediated ROS-dependent PI3K is required for activation of caspase-1 and secretion of IL-1 β and IL-18. Thus, an increase in ROS levels in ATP-treated macrophages results in activation of a single pathway that promotes both adaptation to subsequent exposure to oxidants or inflammation, and processing and secretion of proinflammatory cytokines.

The inflammatory mediator, extracellular ATP, binds to P2 purinergic receptors that are expressed on a wide spectrum of cell types, including macrophages and epithelial cells (1). The P2 receptors can be classified into two families, the P2X ligand-gated cation channels and the G protein-coupled P2Y receptors. The only known physiological ligand for P2X receptors is extracellular ATP, whereas remaining P2Y receptors can interact with ATP and other nucleotides such as UTP, UDP, and ADP (1).

P2X₇ plays a key role in cells from the immune system. Depending on the cell type, treatment with ATP leads to permeabilization of the plasma membrane, cell death, cell prolif-

¹ To whom correspondence should be addressed: P.O. Box 2039, Merced, CA 95344. Tel.: 209-724-2948; Fax: 209-724-2912; E-mail: dojcius@ucmerced.edu.

eration, shedding of cell-adhesion molecules, killing of intracellular pathogens, and secretion of mature IL-1 β^2 and IL-18 (2–4). Whereas the pathways leading from P2X₇ ligation to the different cell responses remain to be characterized in most cases, ATP has been shown to activate various cell signaling mediators, including ERK1/2, PI3K, calcium fluxes, and p38 MAP kinases (5–8).

The proinflammatory cytokines IL-1 β and IL-18 play an important role in fever, septic shock, and inflammatory disease (9). In macrophages, their production and secretion are therefore tightly controlled, requiring typically two separate signals (10, 11). Priming of macrophages with pathogen-associated molecular patterns such as LPS is sufficient to stimulate synthesis of pro-IL-1 β , but secretion of the mature cytokine requires its cleavage by caspase-1. Caspase-1, in turn, is expressed constitutively as an inactive pro-caspase-1. Cleavage and activation of caspase-1 takes place in association with protein complexes termed inflammasomes, of which there are two types. The inflammasome that is activated after P2X₇ ligation contains the adaptor molecule ASC (apoptosis-associated speck-like protein containing a CARD), cardinal, and the NOD-like receptor family member, Nalp3 (also known as cryopyrin). The Nalp3 inflammasome can be activated by "danger signals" (dangerassociated molecular patterns or DAMP) released from stressed or infected eucaryotic cells, such as ATP or uric acid crystals (10, 11), which by themselves do not promote synthesis of the cytokines. LPS priming can increase the efficiency of ATP-mediated caspase-1 activation, but is not required (12, 13). Thus, a pathogen must both express a pathogen-associated molecular pattern capable of driving cytokine synthesis, and be viewed as potentially dangerous to the host organism, for mature IL-1 β and IL-18 to be secreted efficiently.

 $P2X_7$ ligation can lead to pore formation and cytosolic K^+ depletion, and depleting K^+ with ionophores without extracel-

^{*} This work was supported by a fellowship from the Conselho Nacional de Desenvolvimento Cientifico e Technologico do Brasil (CNPq), the University of California, and National Institutes of Health Grant HL37556. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

² The abbreviations used are: IL, interleukin; BzATP, 2',3'-O-(4-benzoylbenzoyl)-ATP; DCF, 2',7'-dichlorofluorescein; DPI, diphenyleneiodonium chloride; iPLA₂, calcium-independent phospholipase A₂; NAC, N-acetylcysteine; Nox, NADPH oxidase complex; oxATP, periodate-oxidized ATP; PLA₂, phospholipase A₂; PTEN, phosphatase and tensin homologue deleted from chromosome 10; ROS, reactive oxygen species; Pl3K, phosphatidyl-inositol 3-kinase; Z, benzyloxycarbonyl; fmk, fluoromethyl ketone; LPS, lipopolysaccharide; Ab, antibody; ELISA, enzyme-linked immunosorbent assay; GCL, glutamate cysteine ligase; FACS, fluorescence-activated cell sorter; MAPK, mitogen-activated protein kinase.

ATP Induces ROS and Cytokine Secretion

lular ATP treatment results in activation of caspase-1 and secretion of IL-1 β and IL-18 in macrophages that had been primed with LPS (2, 10). Several pathogens that produce toxins that promote host-cell K⁺ efflux can also activate the inflammasome, in the absence of a second signal from danger-associated molecular patterns. It was thus proposed that K⁺ depletion, which may be detected by Nalp3, may be a common mechanism used by different danger-associated molecular patterns and pathogens to activate the inflammasome (11, 14). Nonetheless, K⁺ effluxes have not been reported in cells stimulated with uric acid crystals, which must be endocytosed to activate the inflammasome (15), and some pathogen-associated molecular patterns such as peptidoglycan and bacterial mRNA may activate the Nalp3 inflammasome after being detected in the cytosol, making it likely that a decrease in cytosolic K⁺ concentrations may have its effect on Nalp3 indirectly (10), or macrophages may also use other pathways to transmit signals from danger-associated molecular patterns such as ATP to the inflammasome.

We have therefore addressed the possibility that reactive oxygen species (ROS) produced after ATP treatment of primary macrophages may stimulate caspase-1 activation and processing of IL-1 β and IL-18. The production of ROS such as H₂O₂ was long considered as an undesirable consequence of aerobic respiration, being associated with diseases as diverse as aging, cancer, and neurodegenerative disease (16). More recently, however, it has become clear that H₂O₂ is also a physiological mediator in cell signaling pathways involved in differentiation, proliferation, migration, and cytokine secretion (17, 18). Significantly, an ROS response in psychologically stressed mice leads to caspase-1 activation, secretion of IL-1 β , and up-regulation of plasma IL-18 (19).

Given the ability of ROS to activate PI3K and ERK1/2 (20, 21), we also investigated whether ATP-dependent ROS production could activate PI3K and its downstream mediators. We found that in addition to activating PI3K, probably by inactivating PTEN (phosphatase and tensin homologue deleted from chromosome 10) through glutathionylation, ATP-mediated ROS production can activate ERK1/2 and, subsequently, caspase-1, which is required for IL-1 β and IL-18 processing. In parallel, the PI3K pathway is involved in stimulating transcription of genes involved in glutathione synthesis and an oxidative stress response.

EXPERIMENTAL PROCEDURES

Cells and Reagents—ADP, ATP, BzATP, oxATP, UTP, LY-294002, wortmannin, and diphenyleneiodonium chloride (DPI) were purchased from Sigma, whereas PD98059 was from Calbiochem (La Jolla, CA). Z-YVAD-fmk was from Biovision (Mountain View, CA). The antibodies used for Western blotting were anti-p44/p42 MAPK (Thr²⁰²/Tyr²⁰⁴), anti-rabbit p44/p42 and anti-p38 (Tyr(P)^{180/182}), pAKT (Thr³⁰⁸), from Cell Signaling Technology (Beverly, MA); and Akt1 (C-20), from Santa Cruz Biotechnology (Santa Cruz, CA). The alveolar macrophages, NR8383, were isolated from Sprague-Dawley rats (22). NR8383 macrophages were maintained in F-12K medium (Invitrogen) supplemented with 15% heat-inactivated fetal bovine serum (Invitrogen), 100 units/ml penicillin, and 100 μ g/ml streptomycin at 37 °C in a humidified atmosphere of 5% CO₂.

Measurement of ROS Production by FACS and Fluorescence Microscopy—NR8383 cells were treated with different agonists and inhibitors followed by addition of 2',7'-dichlorofluorescein (DCF) (Molecular Probes, Eugene, OR) for 5 min. The samples were analyzed by FACS with a Guava EasyCyte (Hayward, CA) or a Leica epifluorescence microscope (Mannheim, Germany) at 500 nm.

Immunoblotting for Akt and ERK1/2 Phosphorylation—Proteins from lysed cells were analyzed on a SDS-PAGE 4–20% gel (Bio-Rad) and then transferred to a polyvinylidene difluoride membrane (Bio-Rad). Blots were blocked for 1 h with 5% (w/v) nonfat dried milk in TBST. The membrane was incubated overnight at -4 °C with specific antibodies and then incubated again with the corresponding conjugated anti-mouse, anti-rabbit, or anti-goat IgG horseradish peroxidase. Immunoreactive proteins were detected with the ECL Western blotting detection kit (Amersham Biosciences).

Intracellular Staining for ERK1/2 Phosphorylation—NR8383 cells were pretreated with different agonists or inhibitors and centrifuged for 10 min at $600 \times g$. The pellet was resuspended in ice-cold methanol and then incubated for 30 min at 4 °C. The samples were rinsed with incubation buffer (0.5% bovine serum albumin in phosphate-buffered saline) and then incubated for 1 h at room temperature in incubation buffer with the primary Ab. After rinsing, the samples were treated for 30 min with the secondary fluorescein isothiocyanate-conjugated Ab (Santa Cruz Biotechnology). The samples were then rinsed with phosphate-buffered saline and analyzed by FACS with the Guava EasyCyte.

Immunoprecipitation for PTEN Glutathionylation-Ten million NR8383 cells were lysed for 30 min on ice with a lysis buffer containing 50 mM Hepes, 150 mM NaCl, 50 mM β -glycerophosphate, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 100 mM sodium fluoride, 5 mM GSH, 10 μM diethylenetriaminepentaacetic acid, 0.5% Nonidet-40, 1% Triton X-100, 10% glycerol, 10 ng/ml leupeptin, and 10 ng/ml aprotinin, pH 7.4. The lysates were then centrifuged at 10,000 \times *g* for 10 min and the proteins were collected. Five hundred micrograms of protein was incubated with anti-PTEN Ab overnight at -4 °C. The bond complex was washed with cold lysis buffer, and 40 μ l of the immunoprecipitated complex was loaded on a 4-20% SDS-PAGE gel (Bio-Rad). After electrophoresis, the proteins were revealed with Ab against PTEN (Santa Cruz; dilution 1:1000) or GSH-protein complexes (Virogen, Watertown, MA).

Measurement of gcl and Cytokine Gene Expression—NR8383 cells were cultured in 60-mm Petri dishes and pretreated for 30 min with PD98059 (10 μ M), LY294002 (50 μ M), or wortmannin (100 nM), followed by ATP (3 mM), BzATP (1 mM), UTP (1 mM), ADP (0.4 mM), or control buffer for 5 min. The cells were then centrifuged at 600 \times g at 4 °C for 10 min. When the cells were pretreated with oxATP (0.3 mM), the time of incubation was 2 h.

After centrifuging the cells, the RNA extraction was performed with RNEasy Minikit (250) from Qiagen (Valencia, CA), following the manufacturer's instructions, with an additional step where 1 unit/ μ l of RNase-free DNase (Fisher, Lafayette,



CO) was added for 15 min after cell lysis. The reverse transcriptase assay was performed using TaqMan-Reverse Transcription Reagents (Applied Biosystem, Foster City, CA) with a final volume of 40 μ l. The reaction cycle was performed on a Eppendorf Termocycler for 45 min (25 °C for 10 min; 48 °C for 30 min; 95 °C for 5 min). Approximately 1 μ g of cDNA was used for a real-time PCR using primers specific for *gclc* and *gclm*. The reaction was performed using SYBR Green Jump StartTM, Taq Ready MixTM for quantitative PCR (Sigma). The reverse transcriptase-PCR was performed on a ×3000 Stratagene Thermocycler with a pre-heating cycle for 10 min at 95 °C and 50 cycles, then 95 °C for 25 s, 60 °C for 40 s, and 70 °C for 40 s.

The sequences of the *gclc* primers were: 5'-ATGGAGGTA-CAGTTGACAGAC-3', sense; and 5'-ACGGCGTTGCCACC-TTTGCA-3', antisense. For *gclm*, the primers were: 5'-GCTG-TACCAGTGGGCACAG-3', sense; and 5'-GGCTTCAATGT-CAGGGATGC-3', antisense. The *il-18* primers were: 5'-ATA-TCGACCGAACAGCCAAC-3', sense; and 3'-TAGGGTCAC-AGCCAGTCCTC-5', antisense. As a control gene, we used *gapdh*: 5'-ACCCCCAATGTATCCGTTGT-3', sense; and 5'-TACTCCTTGGAGGCCATGT-3', antisense.


Measurement of Caspase-1 Activity by FACS—Caspase-1 activity was measured in NR8383 cells using a caspase assay kit, carboxyfluorescein Flica (Immunochemistry Technologies, Bloomington, MN). In brief, 10^6 cells were incubated with different agonists or inhibitors followed by addition of the caspase-1 fluorigenic substrate, FAM-VAD-fmk (20 μ M). As a control for specificity, cells were also incubated with the caspase-1 inhibitor, Z-YVAD-fmk, before adding FAM-VAD-fmk. Fluorescence was measured using the Guava EasyCite.

Quantification of Cytokine Release—Ten million NR8383 cells were primed with 1 μ g/ml LPS for 2 h at 37 °C, and then treated with 2 μ M DPI for 10 min, 50 μ M Z-YVAD-fmk for 30 min, or LY294002 for 10 min. Finally, the cells were stimulated with 3 mM ATP or control buffer for 6 h. The cells were then spun down and the supernatant collected. The ELISA analysis of the supernatant was performed following the manufacturer's protocol for IL-18 (BIOSOURCE, Carlsbad, CA) and IL-1 β (Pierce Biotechnology).

Statistical Analysis—The statistical analysis was performed using GraphPad InsTat software (GraphPad Software Inc., version 4.0) by Tukey test and was considered significant at p < 0.05.

RESULTS

Extracellular ATP Induces ROS Production in Primary Macrophages—Stimulation of primary rat microglia with the $P2X_7$ agonist, BzATP, leads to release of large amounts of superoxide (23). To determine whether stimulation of primary alveolar macrophages with ATP may also result in production of ROS, macrophages were preincubated with the ROS-sensitive dye, DCF, before treating with 3 mM ATP for 5 min. ATP treatment caused the fluorescence of DCF to increase dramatically, as measured by FACS, compared with background controls (Fig. 1A). A comparable increase in fluorescence was achieved by treating macrophages with 1 mM H₂O₂, and the ATP-induced increase in ROS levels could be inhibited by *N*-acetylcysteine (NAC) (Fig. 1A).






FIGURE 1. ATP induces ROS production in macrophages. A, left, alveolar macrophages were preincubated with an ROS-sensitive dye, DCF (5 μ M), for 5 min, before treating with 3 mM ATP for another 5 min at 37 °C. Enhancement in DCF fluorescence was measured immediately in a FACS, which showed a large increase in fluorescence in ATP-treated macrophages, compared with DCF-labeled untreated controls. A, right, DCF fluorescence was quantified as the mean fluorescence measured by FACS. Preincubation of macrophages with 25 mm NAC for 5 min before ATP treatment abrogated the increase in ROS production. As a positive control, maximal ROS production was measured when untreated macrophages were incubated with 1 mM H_2O_2 for 5 min. p < 0.001 for cells treated with ATP, compared with cells treated with control buffer, or cells treated with ATP with NAC. B, macrophages were preincubated with DCF and then treated with control buffer (left) or 3 mM ATP (right) for 5 min, and visualized immediately with a fluorescence microscope. Phase-contrast microscopy (top panels) does not show obvious morphological changes in macrophages due to ATP treatment. Green fluorescence (bottom panels) was emitted from cells that had been treated with ATP (right, bottom) but not from untreated controls (left, bottom). C, ROS production was maximal after a 5-min incubation with 3 mM ATP, and returned to basal levels within 15 min, as measured by FACS of DCF-labeled cells. All experiments were performed in triplicate at least 3 times on separate days. The values show averages and S.D. from 3 samples of a representative experiment.




FIGURE 2. Ligation of several purinergic receptors can stimulate ROS production in macrophages. *A*, incubation of DCF-labeled macrophages with 3 mm ATP, 3 mm UTP, 0.4 mm ADP, or 0.1 mm UDP results in an increase in ROS levels in




FIGURE 3. Treatment of macrophages with ATP results in ROS-dependent PI3K activation and Akt phosphorylation. Macrophages were pretreated for 5 min with 25 mm NAC or 50 μ m of the PI3K inhibitor, LY294002, for 5 min, and incubated for 5 min with 3 mm ATP. Akt phosphorylation was determined by Western blot, using an Ab recognizing Akt phosphorylated on residue Thr³⁰⁸. The Western blot is representative of three experiments performed on separate days.

ATP-induced ROS production was also confirmed by viewing ATP-treated macrophages by fluorescence microscopy (Fig. 1*B*). Furthermore, the increase in ROS levels was transient. By FACS, ROS production was detectable within 0.5 min of ATP stimulation, rose to maximal levels within 5 min, and subsided to basal levels by 15 min (Fig. 1*C*).

Ligation of $P2X_7$ and Other Purinergic Receptors Leads to ROS Production—Besides expressing the purinergic receptor, $P2X_7$, rat alveolar macrophages express other purinergic receptors, which can be stimulated by ATP, ADP, and UTP (24, 25). All of these nucleotides, including UDP, can promote high levels of ROS production (Fig. 2A). At least part of the ATP-mediated response is due to the $P2X_7$ receptor, as it can be blocked partially by pretreatment with the irreversible $P2X_7$ antagonist, oxATP, and can be stimulated with the $P2X_7$ agonist, BzATP (26) (Fig. 2, *B* and *C*). As incubation with extracellular ADP, UDP, and UTP can also induce ROS production, these results suggest that ligation of $P2X_7$ ligation and other purinergic receptors, possibly $P2X_4$, $P2Y_1$, $P2Y_2$, $P2Y_6$, or $P2Y_{12}$ (24), can all lead to activation of enzymes that result in ROS production.

Ligation of Purinergic Receptors Leads to Activation of the PI3K Pathway—Extracellular ATP can activate PI3K in macrophages and other cell types (6, 8, 27). In many cell types, PI3K phosphorylates and activates the downstream Ser/Thr kinase, Akt/PKB, which promotes survival or controls metabolism through phosphorylation of multiple targets (28). Although oxidants are known to stimulate the PI3K/Akt pathway (29, 30), the mechanism linking P2 receptor ligation with PI3K activation had not been elucidated. We therefore explored the possibility that ATP-mediated ROS production could activate the PI3K pathway in alveolar macrophages, by measuring phosphorylation of Akt by immunoblots using Ab against a phosphorylated residue of Akt (residue Thr³⁰⁸) that leads to Akt activation in different cell types. As shown in Fig. 3, a short incubation of

macrophages, as measured by FACS of DCF-stained macrophages. p < 0.01 for cells treated with ATP, compared with cells treated with control buffer. *B*, preincubation of macrophages with 0.3 mM of the P2X₇ antagonist, oxATP, for 2 h inhibits partially ATP-mediated ROS production due to treatment with 3 mM ATP for 5 min. p < 0.05 for cells treated with oxATP and ATP, compared with cells treated with ATP. *C*, incubation with 1 mM of the P2X₇ agonist, B2ATP, for 5 min induces as much ROS production as 3 mM ATP. p < 0.001 for cells treated with B2ATP, compared with control buffer. The values show averages and S.D. from 3 samples of a representative experiment, and represent results obtained from at least three representative experiments.

macrophages with ATP caused Akt phosphorylation to increase significantly, consistent with previous reports in macrophages and astrocytes (8, 27). The increase in Akt phosphorylation could be inhibited by co-treatment of macrophages with NAC (Fig. 3, *lane 3*), suggesting that ATP-induced ROS production leads to Akt phosphorylation. In addition, ATPinduced Akt phosphorylation was blocked almost completely by pre-treatment of macrophages with the PI3K inhibitor, LY294002 (Fig. 3, *lane 4*), implying that ATP-mediated ROS production results in PI3K activation and subsequently to Akt phosphorylation/activation.

ROS-dependent PI3K Activation Leads to ERK1/2 Phosphorylation—Recent studies have shown that ATP treatment of thymocytes and macrophages results in phosphorylation of ERK1/2, which is downstream from PI3K activation (6, 8). To investigate whether ROS-dependent PI3K activation can in turn lead to ERK1/2 activation, we stimulated alveolar macrophages with ATP in the presence of antioxidants or PI3K inhibitors, and measured ERK1/2 phosphorylation by immunoblot, using Ab against phosphorylated residues of ERK1/2 (residues Thr^{202} and Tyr^{204}) that lead to ERK1/2 activation (31). Thus, ATP stimulation of macrophages led to ERK1/2 phosphorylation within 1 min, consistent with the time course of ROS production after ATP treatment (Fig. 1C), which could be inhibited by NAC and the ERK1/2 inhibitor, PD98056 (Fig. 4A). Interestingly, the time course of ERK1/2 phosphorylation was also similar to Akt phosphorylation (Fig. 4A), although Akt phosphorylation subsided after 10 min, as observed for ATPinduced ROS production (Fig. 1C). ERK1/2 phosphorylation was confirmed by measuring staining with Ab against phosphorylated ERK1/2 by FACS. Short ATP treatment led to ERK1/2 phosphorylation, which could be inhibited partially by the PI3K inhibitors, wortmannin (Fig. 4, *B* and *C*) or LY294002 (Fig. 4*C*), or the ERK1/2 inhibitor, PD98056 (Fig. 4, B and C). Again, ERK1/2 phosphorylation was inhibited by co-treatment with NAC (not shown). Taken together, the results imply that ATP treatment leads to ROS production, which activates PI3K, and PI3K in turn activates Akt and ERK1/2.

ATP-mediated Glutathionylation of PTEN Correlates with Activation of the PI3K Pathway—The phosphatase, PTEN, removes the 3'-phosphate of phosphatidylinositol 3,4,5triphosphate, thus inhibiting PI3K signaling. Previous studies have revealed that PTEN can be inhibited reversibly by H_2O_2 (32, 33). Moreover, oxidized cysteines can then form a disulfide bond with glutathione (GSH), the main antioxidant present in the cell cytosol. A number of signaling proteins have recently been shown to undergo glutathionylation, including proteintyrosine phosphatases and transcription factors (34–38). But as there are no known examples for activating kinases through glutathionylation, we reasoned that inactivation of PTEN through glutathionylation could result in de facto activation of the PI3K pathway.

To test this hypothesis, macrophages were treated with ATP, lysed in a GSH-rich lysis buffer, and proteins were then immunoprecipitated with PTEN-conjugated beads and submitted to electrophoresis. Immunoblotting with an Ab against GSH revealed that a sizable fraction of PTEN exists in a monomeric form that can be recognized by the anti-GSH Ab even in




FIGURE 4. ATP-dependent ROS production and PI3K activation are upstream from ERK1/2 phosphorylation. A, macrophages were incubated with 3 mM ATP, and cells were lysed at different times after the addition of ATP. ERK1/2 phosphorylation was determined by Western blot, probing with an Ab recognizing ERK1/2 phosphorylated on residues Thr²⁰² and Tyr²⁰⁴. Akt phosphorylation was measured with an Ab recognizing Akt phosphorylated on residue Thr³⁰⁸. The Western blot is representative of three experiments performed on separate days. B, ERK1/2 phosphorylation was confirmed by FACS. Macrophages were pretreated for 5 min with control buffer (left panel) 1 μ M of the PI3K inhibitor, wortmannin (*middle panel*), or 10 μ M of the ERK1/2 inhibitor, PD98056 (right panel), for 5 min, and incubated for 5 min with 3 mM ATP. ERK1/2 phosphorylation was measured by FACS, after incubating permeabilized cells with the Ab recognizing phosphorylated ERK1/2. C, ERK1/2 phosphorylation was quantified as the mean fluorescence measured by FACS. Preincubation of macrophages with the ERK1/2 inhibitor, PD98056, or the PI3K inhibitors, wortmannin or LY294002, for 5 min before ATP treatment decreased significantly the extent of ERK1/2 phosphorylation. p < 0.001 for cells treated with wortmannin and ATP, compared with cells treated with ATP. The results are representative of at least two experiments performed on separate days.

untreated macrophages, with a smaller fraction of PTEN being found in a high molecular weight complex (Fig. 5*A*). But the amount of PTEN in both the monomeric glutathionylated form and in the high molecular weight complex increased significantly after a 3-min incubation with ATP (Fig. 5*A*). Treatment of the immunoprecipitate with the reducing agent, dithiothreitol, before electrophoresis resulted in disappearance of both the monomeric and multimeric PTEN (Fig. 5*A*), demonstrating that the Ab recognized only the glutathionylated form of PTEN.

ATP Induces ROS and Cytokine Secretion




FIGURE 5. ATP-dependent ROS production induces glutathionylation of PTEN. Macrophages were pretreated for 5 min with control buffer or 3 mm ATP for 1 min. Cells were lysed, and the proteins were immunoprecipitated overnight with PTEN-conjugated beads. A, the extent of glutathionylation was determined by Western blot, using an Ab recognizing GSH. The anti-GSH Ab revealed the presence of immunoprecipitated protein both as a monomer corresponding to the molecular mass of PTEN (60 kDa) or a larger complex (200 kDa). The level of glutathionylation of PTEN in both monomeric and multimeric forms increases after ATP stimulation of macrophages. Treatment of the immunoprecipitate with the reducing agent dithiothreitol before electrophoresis dissociates GSH from all proteins. B, the results were confirmed by reprobing the same membrane with an Ab recognizing total PTEN. The anti-PTEN Ab also revealed the presence of PTEN in monomers and a larger complex. Macrophage stimulation with ATP causes the amount of PTEN in the larger complex to increase slightly. Treatment with the reducing agent dithiothreitol causes PTEN to dissociate from the larger complex. The Western blots are representative of two experiments performed on separate days.

Reprobing the same membrane with an Ab against PTEN verified the presence of PTEN (60 kDa) in both the treated and untreated macrophages (Fig. 5*B*). The anti-PTEN Ab also confirmed the presence of PTEN in the high molecular weight complex, whose levels increased after the 3-min incubation with ATP (Fig. 5*B*). As expected, dithiothreitol dissociated PTEN from the multimeric complex, without affecting the presence of the monomeric PTEN (Fig. 5*B*). Thus, ATP-dependent glutathionylation of PTEN correlates with ATP-dependent activation of PI3K and is likely to contribute to activation of the PI3K pathway.

ROS Production Results in a PI3K-dependent Redox Response through Expression of Genes Involved in GSH Synthesis—GSH is the most abundant intracellular nonprotein thiol and most important antioxidant in the cytosol. GSH is synthesized through the sequential action of glutamate cysteine ligase (GCL) and glutathione synthase (GS) (39, 40). The rate-limiting enzyme in GSH synthesis, GCL, is composed of two subunits, the catalytic (GCLC) and modulatory (GCLM) subunits, which are encoded by separate genes, *gclc* and *gclm*, that are regulated independently in response of oxidative stress.

As GCL plays a key role in resistance to ROS-mediated oxidative stress (41, 42), we determined whether ATP treatment of macrophages may affect *gcl* expression by real-time PCR, using primers specific for *gclc* and *gclm*. Thus, short incubation of




FIGURE 6. Stimulation of macrophages with ATP results in PI3K- and **ERK1/2-dependent up-regulation of genes involved in GSH synthesis.** *A*, incubation of macrophages with 3 mM ATP, 3 mM UTP, or 0.4 mM ADP for 20 min, followed by an additional 6 h in the absence of nucleotides results in an increased expression of *gclc* and *gclm*, as measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with control buffer; and p < 0.01 for *gclm* of cells treated with ATP, compared with cells treated with control buffer; and p < 0.01 for *gclm* of cells treated with ADP, compared with cells treated with control buffer. *B*, macrophages were pretreated for 5 min with the PI3K inhibitors, LY294002 (50 μ M), or the ERK1/2 inhibitor, PD98056 (10 μ M), for 5 min, and then incubated for 5 min with 3 mM ATP. Expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with ATP, compared with cells treated with 3 mM ATP. Expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with 3 mM ATP. Expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with ATP expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with ATP expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with ATP expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with ATP expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of cells treated with ATP, compared with cells treated with ATP expression of *gclm* and *gclc* was measured by real-time PCR. p < 0.001 for *gclm* of

macrophages with ATP led to significant up-regulation of both the *gclc* and *gclm* genes, whereas smaller up-regulation was observed when macrophages were stimulated with UTP or ADP (Fig. 6*A*). Incubation with the P2X₇ agonist, BzATP, also resulted in a large increase in *gclc* and *gclm* expression, whereas the antagonist oxATP inhibited ATP-induced *gclm* and *gclc* up-regulation (not shown), suggesting that ligation of several purinergic receptors, including P2X₇, may stimulate *gcl* up-regulation. The expression of *gcl* was similar to control levels when ATP-treated macrophages were also treated with catalase (not shown), which converts H₂O₂ produced on the outside of cells into water and oxygen, implying that ATP-mediated H₂O₂ pro-



duction is responsible for regulation of *gclc* and *gclm* expression.

Given the effect of ATP-mediated ROS production on PI3K activation, we then investigated whether the PI3K pathway may influence *gcl* expression. Both the PI3K inhibitors, LY294002 and wortmannin (shown for LY294002 in Fig. 6*B*), and the ERK1/2 inhibitor, PD98056 (Fig. 6*B*), blocked ATP-dependent *gcl* up-regulation. Taken together, these results suggest that ATP ligation of $P2X_7$ results in an increase in ROS levels, which activate PI3K and subsequently ERK1/2, which in turn regulates the oxidative stress response of the cell.

Extracellular ATP Leads to Cytokine Secretion through a Pathway Involving ERK1/2-dependent Caspase-1 Activation—Extracellular ATP stimulates secretion of the key proinflammatory cytokines, IL-1 β and IL-18, through a pathway requiring the presence of P2X₇ (2). P2X₇ ligation by itself does not lead to IL-1 β or IL-18 transcription or translation, but after macrophage stimulation of receptors such as the TLR, P2X₇ ligation by ATP results in activation of caspase-1 and secretion of the mature form of both cytokines. Recently it was shown that an inflammasome is required for ATP-dependent IL-1 β and IL-18 secretion (10), but a molecular pathway linking P2X₇ ligation and the inflammasome was not identified. We therefore explored the possibility that ATP-mediated ROS production may play a role in caspase-1 activation and cytokine secretion.

Caspase-1 activation was quantified by measuring binding to cells of a fluorescently labeled caspase inhibitor by FACS. As measured by real-time PCR, ATP treatment, in the absence of TLR ligands, had no effect on transcription for IL-18 (not shown), in agreement with previous studies on the lack of effect of ATP alone on IL-1 β transcription (2). However, ATP treatment by itself results in caspase activation (Fig. 7*A*). Caspase activation was also inhibited by pretreating the cells with the irreversible caspase-1 inhibitor, Z-YVAD-fmk, before incubation with ATP (not shown), confirming that caspase-1 was activated by ATP. Importantly, ATP-mediated caspase-1 activation was inhibited strongly when macrophages were co-incubated with DPI (Fig. 7*A*), a flavoprotein inhibitor of NADPH oxidase, consistent with the conclusion that ATP-dependent ROS production is responsible for caspase-1 activation.

To determine whether ROS production is sufficient for caspase-1 activation, we then evaluated whether the PI3K pathway may be involved. To examine the role of a downstream mediator in the pathway, we measured the effect of the ERK1/2 inhibitor on caspase-1 activation. The ERK1/2 inhibitor, PD98056, blocked essentially all of the ATP-mediated caspase-1 activation (Fig. 7*B*). Conversely, the irreversible caspase-1 inhibitor had no effect on ATP-dependent ROS production (not shown). These results demonstrate that ATP-mediated ROS production leads to ERK1/2 activation, which in turn regulates activation of the inflammasome.

Because ATP alone cannot induce synthesis of cytokines (2), the role of ROS production and caspase-1 activation in cytokine secretion was then addressed using macrophages that had been primed with the TLR4 ligand, LPS, before stimulating the macrophages with ATP. IL-1 β and IL-18 secretion was quantified by ELISA. Incubation of primed macrophages with ATP led to secretion of both IL-1 β and IL-18, which in both cases could be




FIGURE 7. **ATP-dependent ROS production and ERK1/2 activation are upstream from caspase-1 activation.** *A*, macrophages were stained with the fluorescent caspase substrate, FAM-VAD-fmk, pretreated for 10 min with the redox inhibitor, DPI (2 μ M), and then incubated for 6.5 or 12 h with 3 mM ATP. Caspase-1 was measured by FACS. The specificity of caspase-1 activation was verified by pretreating the stained cells with the irreversible caspase-1 inhibitor, Z-YVAD-fmk. *p* < 0.001 for cells treated with DPI and ATP for 12 h, compared with cells treated with ATP for 12 h. *B*, stained macrophages were pretreated for 5 min with 10 μ M of the ERK1/2 inhibitor, PD98056, for 5 min, before incubation for 5 min with 3 mM ATP. *p* < 0.001 for cells treated with ATP alone. The values show averages and S.D. from experiments performed in triplicate, and represent results obtained from at least two representative experiments.

inhibited by pretreatment with DPI (shown for IL-1 β in Fig. 8), consistent with our observations that DPI blocks caspase-1 activation (Fig. 7*A*). Cytokine secretion was also inhibited by preincubation with the PI3K inhibitor, LY294002, or the caspase-1 inhibitor, Z-YVAD-fmk (Fig. 8). Thus, ATP-mediated ROS production in LPS-primed macrophages leads to




FIGURE 8. **ATP stimulation of macrophages leads to IL-1** β secretion **through a pathway requiring ROS production and PI3K activation.** Macrophages were primed with 1 μ g/ml LPS for 2 h at 37 °C, before treating the macrophages with the caspase-1 inhibitor, Z-YVAD-fmk (50 μ M) for 30 min, DPI (2 μ M) for 10 min, or LY294002 (50 μ M) for 10 min. The cells were then stimulated with 3 mM ATP for 6 h. Secretion of IL-1 β was measured by ELISA. p < 0.001 for cells treated with ATP and Z-YVAD-fmk, DPI, or LY294002, compared with cells treated with ATP alone. The experiment was performed twice in duplicate, and the results represent the average and S.D.

ERK1/2 activation, which is upstream from caspase-1 activation and cytokine secretion.

DISCUSSION

Until recently, the production of H_2O_2 was studied primarily in macrophages and neutrophils. These cells use the NADPH oxidase complex (Nox2) in the plasma membrane to generate H_2O_2 . The primary purpose of the respiratory burst in neutrophils is to kill internalized pathogens; however, in alveolar macrophages, a signaling role for H_2O_2 produced by the respiratory burst may be more important (18). In phagocytes, activation of the immune cells by pathogens leads to assembly of the Nox complex at the plasma membrane, which releases superoxide into the phagosome. Superoxide dismutation then results in production of H_2O_2 . Nonphagocytic cells also express the functional homologues of the Nox catalytic subunit (43), and can generate H_2O_2 at the plasma membrane following stimulation with cytokines and growth factors (44).

We show here that stimulation of alveolar macrophages with ATP and other extracellular nucleotides leads to transient production of high levels of ROS. The effects of the agonist BzATP and the antagonist oxATP suggest that $P2X_7$ ligation is responsible for much of the activity. Although the pathway coupling purinergic receptor ligation with ROS generation remains unknown, it is likely that the Nox complex is activated at the level of the plasma membrane. Localized Nox assembly has previously been reported in lipid rafts in activated microglia and HL-60 cells and in focal complexes in migrating endothelial cells (45, 46), and could also take place near ligated P2X₇, which has been found to localize in lipid rafts in T cells and cells from submandibular glands (47, 48).

What could be the trigger for Nox assembly? Potassium depletion due to ionophore or ATP treatment leads to an influx of Ca²⁺ and the activation of phosphatidylcholine-specific phospholipase C and calcium-independent and -dependent phospholipase A₂ (PLA₂) (49, 50). Calcium-independent PLA₂ (iPLA₂) stimulates the colocalization of caspase-1 and pro-IL-1 β in secretory lysosomes, which could favor caspase-1 acti-

vation and pro-IL-1 β cleavage and perhaps its subsequent shedding (10, 51). It has been proposed that Nalp3 may also respond to cytosolic lipids such as arachidonic acid and lysophospholipids generated by iPLA₂ (10). Phospholipase-generated signals in ATP-treated macrophages may also synergize with elevated cytosolic Ca²⁺ in stimulating ROS production, as Ca²⁺ levels or iPLA₂ activity in various cell types can modulate ROS production (52–54). Conversely, elevated ROS levels can activate iPLA₂ or trigger Ca²⁺ fluxes (55, 56), suggesting that P2X₇-dependent inflammasome activation could conceivably involve a cooperative loop between ROS generation, Ca²⁺ fluxes, and iPLA₂ activation.

ROS is involved in diverse receptor systems, including tumor necrosis factor- α , epidermal growth factor, platelet-derived growth factor, the T and B cell receptors, and insulin (17, 52, 57-60). Signal activation is often thought to occur through ROS-mediated inhibition of protein-tyrosine phosphatases, which shifts the equilibrium in favor of kinase activation. An essential cysteine in the active site of protein-tyrosine phosphatases has been identified as target for oxidation by H₂O₂, which can then undergo reversible glutathionylation (35-37). Previous studies have shown that oxidative inactivation of phosphatases leads to sustained activation of the corresponding kinases (44). As activation of kinases through glutathionylation has not been reported, we investigated the possibility that the cognate phosphatase, PTEN, could be inactivated. In fact, PTEN is glutathionylated soon after ATP stimulation of macrophages. ROS production and PTEN glutathionylation in ATP-stimulated macrophages could thereby shift the balance in favor of PI3K, which leads in turn to phosphorylation of Akt. In agreement with previous studies (5, 6), we find that ERK1/2 is also activated in ATP-treated cells, although the mechanism for activation of the PI3K pathway was not identified.

An important feature of any signaling pathway is reversibility. For ROS to regulate PTEN reversibly, it is critical to prevent oxidation of the active site Cys of PTEN beyond sulfenic acid (S-OH). The enzyme is protected against further, irreversible oxidation by reaction with GSH to form the mixed disulfide (44). Glutathionylation of PTEN leads to formation of high molecular weight oligomers, which can be reversed in lysed cells by incubation with a reducing agent. Treatment of cells with oxidants or the proinflammatory cytokines, tumor necrosis factor- α and IL-1 β , causes an initial depletion of GSH, followed by recovery and increased synthesis of GSH (39). The rate-limiting enzyme in GSH synthesis is GCL, and its expression is regulated by several transcription factor binding sites, such as AP-1 and antioxidant response elements, in response to oxidants and inflammatory stimuli (39), thus providing an adaptive mechanism to protect the cells during subsequent proinflammatory or oxidant stress. Similarly, we find that gcl expression increases following treatment of macrophages with the proinflammatory mediator, ATP. The up-regulation requires both ROS production and activation of the PI3K pathway.

Unexpectedly, we found that ATP-mediated, ROS-dependent PI3K activation is also involved in activation of caspase-1 and processing of IL-1 β and IL-18. The Nalp3 inflammasome can be activated by stimuli as diverse as ATP, K⁺ ionophores, bacterial toxins, and uric acid crystals (10, 11). It will be intrigu-

ATP Induces ROS and Cytokine Secretion

ing to determine whether any of the cell signaling pathways initiated by stimuli other than ATP may also converge on the inflammasome via ROS.

REFERENCES

- 1. Burnstock, G., and Knight, G. E. (2004) Int. Rev. Cytol. 240, 31-304
- 2. Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., Panther, E., and Di Virgilio, F. (2006) *J. Immunol.* **176**, 3877–3883
- Coutinho-Silva, R., Stahl, L., Raymond, M. N., Jungas, T., Verbeke, P., Burnstock, G., Darville, T., and Ojcius, D. M. (2003) *Immunity* 19, 403–412
- Lammas, D. A., Stober, C., Harvey, C. J., Kendrick, N., Panchalingam, S., and Kumaratane, D. S. (1997) *Immunity* 7, 433–444
- Gendron, F. P., Neary, J. T., Theiss, P. M., Sun, G. Y., Gonzalez, F. A., and Weisman, G. A. (2003) Am. J. Physiol. 284, C571–C581
- Auger, R., Motta, I., Benihoud, K., Ojcius, D. M., and Kanellopoulos, J. M. (2005) J. Biol. Chem. 280, 28142–28151
- Pfeiffer, Z. A., Aga, M., Prabhu, U., Watters, J. J., Hall, D. J., and Bertics, P. J. (2004) *J. Leukocyte Biol.* 75, 1173–1182
- da Cruz, C. M., Ventura, A. L., Schachter, J., Costa-Junior, H. M., da Silva Souza, H. A., Gomes, F. R., Coutinho-Silva, R., Ojcius, D. M., and Persechini, P. M. (2006) *Br. J. Pharmacol.* 147, 324–334
- 9. Dinarello, C. A. (2006) Am. J. Clin. Nutr. 83, 447S-455S
- 10. Lich, J. D., Arthur, J. C., and Ting, J. P.-Y. (2006) Immunity 24, 241-243
- 11. Meylan, E., Tschopp, J., and Karin, M. (2006) Nature 442, 39-44
- Yamamoto, M., Yaginuma, K., Tsutsui, H., Sagara, J., Guan, X., Seki, E., Yasuda, K., Yamamoto, M., Akira, S., Nakanishi, K., Noda, T., and Taniguchi, S. (2004) *Genes Cells* 9, 1055–1067
- Mariathasan, S., Newton, K., Monack, D. M., Vucic, D., French, D. M., Lee, W. P., Roose-Girma, M., Erickson, S., and Dixit, V. M. (2004) *Nature* 430, 213–218
- Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., and Dixit, V. M. (2006) *Nature* 440, 228–232
- Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006) Nature 440, 237–241
- Tabner, B. J., El-Agnaf, O. M., German, M. J., Fullwood, N. J., and Allsop, D. (2005) *Biochem. Soc. Trans.* 33, 1082–1086
- 17. Rhee, S. G. (2006) Science 312, 1882-1883
- Forman, H. J., and Torres, M. (2002) Am. J. Respir. Crit. Care Med. 166, S4–S8
- Sekiyama, A., Ueda, H., Kashiwamura, S.-i., Sekiyama, R., Takeda, M., Rokutan, K., and Okamura, H. (2005) *Immunity* 22, 669–677
- 20. Qin, S., and Chock, P. B. (2003) Biochemistry 42, 2995-3003
- 21. Lee, S. B., Cho, E. S., Yang, H. S., Kim, H., and Um, H. D. (2005) *Cell. Signal.* 17, 197–204
- Helmke, R. J., Boyd, R. L., German, V. F., and Mangos, J. A. (1987) *In Vitro Cell. Dev. Biol.* 23, 567–574
- Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., and Posmantur, R. (2003) J. Biol. Chem. 278, 13309–13317
- Bowler, J. W., Bailey, R. J., North, R. A., and Surprenant, A. (2003) Br. J. Pharmacol. 140, 567–575
- Zhang, G. H., Helmke, R. J., Mork, A. C., and Martinez, J. R. (1997) J. Leukocyte Biol. 62, 341–348
- 26. North, R. A. (2002) Physiol. Rev. 82, 1013-1067
- Jacques-Silva, M. C., Rodnight, R., Lenz, G., Liao, Z., Kong, Q., Tran, M., Kang, Y., Gonzalez, F. A., Weisman, G. A., and Neary, J. T. (2004) *Br. J. Pharmacol.* 141, 1106–1117

- 28. Brazil, D. P., Park, J., and Hemmings, B. A. (2002) Cell 111, 293-303
- Zhuang, S., and Kochevar, I. E. (2003) *Photochem. Photobiol.* **78**, 361–371
 Klotz, L. O., Schieke, S. M., Sies, H., and Holbrook, N. J. (2000) *Biochem. J.* **352**, 219–225
- Monteiro, H. P., Rocha Oliveira, C. J., Curcio, M. F., Moraes, M. S., and Arai, R. J. (2005) *Methods Enzymol.* 396, 350–358
- Leslie, N. R., Bennett, D., Lindsay, Y. E., Stewart, H., Gray, A., and Downes, C. P. (2003) *EMBO J.* 22, 5501–5510
- Lee, S. R., Yang, K. S., Kwon, J., Lee, C., Jeong, W., and Rhee, S. G. (2002) J. Biol. Chem. 277, 20336–20342
- 34. Kil, I. S., and Park, J. W. (2005) J. Biol. Chem. 280, 10846-10854
- 35. Lee, S. R., Kwon, K. S., Kim, S. R., and Rhee, S. G. (1998) *J. Biol. Chem.* **273**, 15366–15372
- Barrett, W. C., DeGnore, J. P., Konig, S., Fales, H. m., Keng, Y. F., Zhang, Z. Y., Yim, M. B., and Chock, P. B. (1999) *Biochemistry* 38, 6699 – 6705
- Rinna, A., Torres, M., and Forman, H. J. (2006) Free Radic. Biol. Med. 41, 86–91
- Fratelli, M., Goodwin, L. O., Orom, U. A., Lombardi, S., Tonelli, R., Mengozzi, M., and Ghezzi, P. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 13998–14003
- 39. Rahman, I. (2005) Mutat. Res. 579, 58-80
- 40. Forman, H. J., Dickinson, D. A., and Iles, K. E. (2003) *Mol. Aspects Med.* **24**, 189–194
- Ridnour, L. A., Sim, J. E., Choi, J., Dickinson, D. A., Forman, H. J., Ahmad, I. M., Coleman, M. C., Hunt, C. R., Goswami, P. C., and Spitz, D. R. (2005) *Free Radic. Biol. Med.* 38, 1361–1371
- 42. Moellering, D. R., Levonen, A. L., Go, Y. M., Patel, R. P., Dickinson, D. A., Forman, H. J., and Darley-Usmar, V. M. (2002) *Biochem. J.* **362**, 51–59
- 43. Lambeth, J. D. (2004) Nat. Rev. Immunol. 4, 181–189
- 44. Tonks, N. K. (2005) Cell 121, 667–670
- 45. Vilhardt, F., and van Deurs, B. (2004) *EMBO J.* 23, 739-748
- Wu, R. F., Xu, Y. C., Ma, Z., Nwariaku, F. E., Sarosi, G. A., Jr., and Terada, L. S. (2005) *J. Cell Biol.* **171**, 893–904
- 47. Bannas, P., Adriouch, S., Kahl, S., Braasch, F., Haag, F., and Koch-Nolte, F. (2005) *Blood* **105**, 3663–3670
- Garcia-Marcos, M., Perez-Andres, E., Tandel, S., Fontanils, U., Kumps, A., Kabre, E., Gomez-Munoz, A., Marino, A., Dehaye, J. P., and Pochet, S. (2006) J. Lipid Res. 47, 705–714
- 49. Andrei, C., Margiocco, P., Poggi, A., Lotti, L. V., Torrisi, M. R., and Rubartelli, A. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 9745–9750
- 50. Duke, R. C., Witter, R. Z., Nash, P. B., Young, J. D., and Ojcius, D. M. (1994) FASEB J. **8**, 237–246
- MacKenzie, A., Wilson, H. L., Kiss-Toth, E., Dower, S. K., North, R. A., and Surprenant, A. (2001) *Immunity* 15, 825–834
- Kumar Singh, D., Kumar, D., Siddiqui, Z., Kumar Basu, S., Kumar, V., and Rao, K. V. (2005) *Cell* **121**, 281–293
- Gong, M. C., Arbogast, S., Guo, Z., Mathenia, J., Su, W., and Reid, M. B. (2006) *J. Appl. Physiol.* **100**, 399–405
- Colston, J. T., de la Rosa, S. D., Strader, J. R., Anderson, M. A., and Freeman, G. L. (2005) *FEBS Lett.* 579, 2533–2540
- Bogeski, I., Bozem, M., Sternfeld, L., Hofer, H. W., and Schulz, I. (2006) Cell Calcium 40, 1–10
- 56. Zima, A. V., and Blatter, L. A. (2006) Cardiovasc. Res. 71, 310-321
- Kamata, H., Honda, S.-i., Maeda, S., Chang, L., Hirata, H., and Karin, M. (2005) Cell 120, 649 – 661
- 58. Meng, T. C., Fukada, T., and Tonks, N. K. (2002) Mol. Cell 9, 387-399
- 59. Finkel, T. (2003) Curr. Opin. Cell Biol. 15, 247-254
- 60. Nathan, C. (2003) J. Clin. Investig. 111, 769-778

ATP Activates a Reactive Oxygen Species-dependent Oxidative Stress Response and Secretion of Proinflammatory Cytokines in Macrophages

Cristiane M. Cruz, Alessandra Rinna, Henry Jay Forman, Ana L. M. Ventura, Pedro M. Persechini and David M. Ojcius

J. Biol. Chem. 2007, 282:2871-2879. doi: 10.1074/jbc.M608083200 originally published online November 27, 2006

Access the most updated version of this article at doi: 10.1074/jbc.M608083200

Alerts:

- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 59 references, 21 of which can be accessed free at http://www.jbc.org/content/282/5/2871.full.html#ref-list-1